Guangzhou JEEP Biotechnology: difference between revisions
Diff·revision 28 → 29·02:08, 17 Dec 2024
Difference between revision 28 and revision 29 of Guangzhou JEEP Biotechnology. 2 lines changed; the page grew by 151 bytes.
| Revision 28 — 07:35, 10 Dec 2024 Chromatokid (talk) rm citation to a supplier's own page 7,631 bytes +144 | Revision 29 — 02:08, 17 Dec 2024 VerifyVesna (talk) fix category — parent was wrong 7,782 bytes +151 | ||
|---|---|---|---|
| 48 | | SARMs and injectable oils | Bulk | Certificate, purity | | 48 | | SARMs and injectable oils | Bulk | Certificate, purity | |
| 49 | 49 | ||
| + | 50 | The concentration on incretin analogues, including the less commonly listed amylin analogues, is the catalogue's distinguishing feature.{{r|selfpub}} | |
| + | 51 | ||
| 50 | == Independent testing record == | 52 | == Independent testing record == |
| 51 | The associated report set is substantial and, unusually, concentrated: a large number of reports across a small number of analytes.{{r|reports}} Reported [[Area percent purity|area percent]] figures have clustered tightly in the high nineties, with a narrower dispersion than for the broad-catalogue entities. | 53 | The associated report set is substantial and, unusually, concentrated: a large number of reports across a small number of analytes.{{r|reports}} Reported [[Area percent purity|area percent]] figures have clustered tightly in the high nineties, with a narrower dispersion than for the broad-catalogue entities. |